Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Year-over-year total asset growth rate
3Y CAGR
-18.2%/yr
vs +85.6%/yr prior
Acceleration
-103.8pp
Decelerating
Percentile
P77
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 15.80% |
| Q3 2025 | 0.34% |
| Q2 2025 | -12.26% |
| Q1 2025 | 55.22% |
| Q4 2024 | -11.06% |
| Q3 2024 | 28.97% |
| Q2 2024 | -7.47% |
| Q1 2024 | 52.51% |
| Q4 2023 | -18.19% |
| Q3 2023 | -3.81% |
| Q2 2023 | -10.71% |
| Q1 2023 | -0.02% |
| Q4 2022 | 28.84% |
| Q3 2022 | -7.96% |
| Q2 2022 | 6.85% |
| Q1 2022 | 10.19% |
| Q4 2021 | -10.08% |
| Q3 2021 | -3.37% |
| Q2 2021 | -2.89% |
| Q1 2021 | 51.59% |
| Q4 2020 | -4.45% |
| Q3 2020 | -5.98% |
| Q2 2020 | -0.95% |
| Q1 2020 | -4.51% |
| Q4 2019 | 67.96% |
| Q3 2019 | 3.86% |
| Q2 2019 | 0.86% |
| Q1 2019 | -2.06% |
| Q4 2018 | 205.48% |
| Q3 2018 | -1.15% |
| Q2 2018 | -11.10% |
| Q1 2018 | 43.96% |
| Q4 2017 | -15.19% |
| Q3 2017 | -9.61% |
| Q2 2017 | -9.29% |
| Q1 2017 | -12.05% |
| Q4 2016 | 12.55% |
| Q3 2016 | 49.86% |
| Q2 2016 | -9.59% |
| Q1 2016 | -15.06% |